Navigation Links
Discovery of new cause of mental retardation simplifies search for treatments
Date:1/24/2008

Leuven, Belgium − 2 to 3 children in 100 are born with a mental handicap. This can be caused by a genetic defect, but in 80% of the cases scientists do not know which genes are responsible. Now, VIB researchers connected to the Katholieke Universiteit Leuven, in collaboration with an Australian research team, have discovered that, in a portion of these patients, the mental retardation is caused by a twofold production of two proteins (HSD17B10 and HUWE1). This is the first time that scientists have found that duplication of a protein leads to mental retardation. The discovery offers promising possibilities in the search for remedies, because its easier to reduce an over-production of a protein than to repair a defective protein or to replace a missing protein.

Defects on the X-chromosome

Mental retardation occurs in 2 - 3% of our population. This can be attributed to external factors (such as a shortage of oxygen at birth) or to defects in the DNA. When the cause is genetic (hereditary), identifying the precise defect is crucial for the patients medical support or for assessing the risk of having children. Scientists estimate that, in about 30% of the patients, a defect on the X-chromosome is the underlying cause. This is called X-linked mental retardation (XLMR). In over half of the XLMR patients, the gene responsible has not yet been identified.

2 proteins in the leading role

Guy Froyen and his colleagues in the Human Genome Laboratory (VIB K.U. Leuven) teamed up with Jozef Gczs research group (University of Adelaide, Australia) to look for new genes that might lie at the basis of XLMR. With the aid of a very specialized molecular technology (X-chromosome specific array CGH), they studied the genes of some 300 XLMR families. In 6 of the families, they discovered that a certain part of the X-chromosome had been duplicated. Because of this duplication, two proteins, HSD17B10 and HUWE1, were produced in too high a concentration. The researchers in Leuven also found small alterations in both proteins in other XLMR patients. Through this research, they are uncovering the important role that these proteins play in the development of the brains memory center.

A new mechanism opens possibilities

The VIB scientists research is showing for the first time that the duplication of a chromosome region − whereby proteins are produced in too high a concentration − can lead to mental retardation. This is totally new information in the current understanding of genetic causes of mental retardation without attendant symptoms. Scientists have thought that defects that stop production of a protein, or cause it to be produced in a defective way, could lie at the basis of this disorder. The new discovery that too much of a protein can also cause mental retardation has a major impact on the quest for new therapies or medicines. Indeed, its easier to scale back an over-production of a protein than to repair a defective protein.

Consequences for detecting and treating XLMR

The research being conducted by Guy Froyen and his colleagues presents new possibilities for detecting and treating XLMR. Tests can now be designed with which scientists can look for duplication of, and defects in, HSD17B10 and HUWE1. Developing a new treatment for XLMR, however, will require further research. Scientists must first gain greater insight into the role these proteins play in the body, and more specifically, in the brain. Research models are now being set up for this effort.


'/>"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
3. European Centre for Modern Drug Discovery Established in Hamburg
4. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
5. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
9. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
10. New method of selecting DNA for resequencing accelerates discovery of subtle DNA variations
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):